



VF001 profiled at US conference Symposium on Advanced Wound Care

Brisbane, Australia 4th May 2018: Factor Therapeutics Limited (ASX: FTT, the “Company”), an Australian biomedical company developing therapeutics for advanced wound care, presented its technology and the design and execution of the Phase 2 VF00102 study at the Symposium on Advanced Wound Care (SAWC) Spring meeting in Charlotte, NC.

Factor Therapeutics Director of Research & Development, Dr Gary Shooter said, “Both of the abstracts that were submitted to the meeting were accepted, one as a poster and the other as an oral abstract presentation.

“The poster highlighted the design and current status of our Phase 2 study and the oral presentation focused on the science behind our lead VF001 product and platform technology,” he said.

Factor Therapeutics CEO Dr Ros Wilson said attending the conference was very worthwhile.

“SAWC attracts 2000 delegates from a wide range of stakeholders in wound care, so this was an excellent opportunity for us to meet with potential partners and collaborators,” Dr Wilson said.

“We had a series of very productive meetings, continuing the dialogue around our plans post-readout of VF00102.

“Our goal in attending SAWC was to raise awareness about our technology and continue to build relationships and interest among potential partners. I’m confident we achieved this goal and we will make further progress with these discussions as we move toward completing recruitment and the readout of VF00102,” she said.

-ENDS-

Click [here](#) to view the poster which was presented at SAWC.

Contact for Further Information:

Dr. Rosalind Wilson
Chief Executive Officer
Factor Therapeutics Limited
r.wilson@factor-therapeutics.com

About Factor Therapeutics

Factor Therapeutics Limited (“Factor”) is a biomedical technology company that is developing treatments for acute and chronic wound healing applications. Factor is a clinical stage company with its lead program (VF-001) in Phase II for the treatment of venous leg ulcers (VLUs). The company is also developing solutions for a variety of interventional wound care and serious orphan dermatology conditions. The company’s platform technology originates from the Institute of Health and Biomedical Innovation at the Queensland University of Technology (QUT), Australia. Factor’s shares are traded on the Australian Securities Exchange (ASX) under the ticker FTT. For more information, please visit <https://factor-therapeutics.com>